Effects of Ganoderma lucidum (“lingzhi”) supplementation on blood lipids – a systematic review of clinical trials
DOI:
https://doi.org/10.15584/ejcem.2025.3.19Keywords:
cardiovascular disease, cholesterol, Ganoderma lucidum, lingzhi, lipidsAbstract
Introduction and aim. Impaired blood lipid profile is a major risk factor for cardiovascular disease, the leading cause of mortality worldwide. Supplementation of Ganoderma lucidum (“lingzhi”) has been postulated to have a positive impact on blood lipids. This review aims to evaluate the evidence on this topic.
Material and methods. A systematic search of Google Scholar, PubMed and clinicaltrials.gov databases was performed to identify randomized clinical trials and cross-over trials which assessed the effects of lingzhi supplementation on blood lipids. The gathered data were reviewed and analyzed in accordance with PRISMA guidelines.
Analysis of the literature. Of the 805 records identified in the initial search, a total of 7 studies met all the inclusion criteria and were qualified for the review. None of them reported a statistically significant change in triglycerides, high-density lipoprotein, or low-density lipoprotein during lingzhi supplementation. Only 2 out of 7 trials showed a moderate decrease in total cholesterol level.
Conclusion. There is no evidence to support any effect of G. lucidum supplementation on triglycerides, high-density lipoprotein or low-density lipoprotein. Its influence on total cholesterol also remains highly doubtful based on the present systematic review.
Downloads
References
Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics - 2023 Update: A Report from the American Heart Association. Circulation. 2023;147(8):e93-e621. doi: 10.1161/CIR.0000000000001123
Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021;18(10):689-700. doi: 10.1038/s41569-021-00541-4
Barquera S, Pedroza-Tobías A, Medina C, et al. Global Overview of the Epidemiology of Atherosclerotic Cardio-vascular Disease. Arch Med Res. 2015;46(5):328-338. doi: 10.1016/j.arcmed.2015.06.006
Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommen-dation statement. JAMA. 2016;316(19):1997-2007. doi: 10.1001/jama.2016.15450
Abdul-Rahman T, Bukhari SMA, Herrera EC, et al. Li-pid Lowering Therapy: An Era Beyond Statins. Curr Probl Cardiol. 2022;47(12):101342. doi: 10.1016/j.cpcar-diol.2022.101342
Wachtel-Galor S, Yuen J, Buswell JA, Benzie IFF. Ganoder-ma lucidum (lingzhi or reishi): A medicinal mushroom. In: Herbal Medicine: Biomolecular and Clinical Aspects: Second Edition. ed. Boca Raton, FL: CRC Press/Taylor & Francis; 2011.
Berger A, Rein D, Kratky E, et al. Cholesterol-lowering properties of Ganoderma lucidum in vitro, ex vivo, and in hamsters and minipigs. Lipids Health Dis. 2004;3:1-12. doi: 10.1186/1476-511X-3-1
Wang W, Zhang Y, Wang Z, Zhang J. Ganoderma lucidum polysaccharides improve lipid metabolism against high-fat diet-induced dyslipidemia. Journal of Ethnopharmacology. 2023;309:116321. doi: 10.1016/j.jep.2023.116321
Guo WL, Pan YY, Li L, Li TT, Liu B, Lv XC. Ethanol extract of Ganoderma lucidum ameliorates lipid metabolic disorders and modulates the gut microbiota composition in high-fat diet fed rats. Food Funct. 2018;9(6):3419-3431. doi: 10.1039/c8fo00836a
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyana web and mobile app for systematic reviews. Syst Rev. 2016;5(1):1-10. doi: 10.1186/s13643-016-0384-4
Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration Web site. https://handbook-5-1.cochrane. org/. Accessed December 20, 2024.
Wachtel-Galor S, Szeto YT, Tomlinson B, Benzie IFF. Ga-noderma lucidum (‘Lingzhi’); acute and short-term bio-marker response to supplementation. Int J Food Sci Nutr. 2004;55(1):75-83. doi: 10.1080/09637480310001642510
Wachtel-Galor S, Tomlinson B, Benzie IFF. Ganoderma lucidum (‘Lingzhi’), a Chinese medicinal mushroom: biomarker responses in a controlled human supplemen-tation study . Br J Nutr. 2004;91(2):263-269. doi: 10.1079/ bjn20041039
Gao Y, Lan J, Dai X, Ye J, Zhou S. A Phase I/II Study of Ling Zhi Mushroom Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) Extract in Patients with Type II Diabetes Mellitus. Int J Med Mushrooms. 2004;6(1). doi: 10.1615/intjmedmushr.v6.i1.30
Gao Y, Chen G, Dai X, Ye J, Zhou S. A Phase I/II Study of Ling Zhi Mushroom Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) Extract in Patients with Coronary Heart Disease. Int J Med Mushrooms. 2004;6(4). doi: 10.1615/intjmedmushr.v6.i4.30
Chu TTW, Benzie IFF, Lam CWK, Fok BSP, Lee KKC, Tomlinson B. Study of potential cardioprotective effects of Ganoderma lucidum (Lingzhi): results of a controlled hu-man intervention trial. Br J Nutr. 2012;107(7):1017-1027. doi: 10.1017/S0007114511003795
Klupp NL, Kiat H, Bensoussan A, Steiner GZ, Chang DH. A double-blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome. Sci Rep. 2016;6: 29540. doi: 10.1038/srep29540
Babamiri S, Mojani Qomi MS, Shiehmorteza M. The Ef-ficacy of italic Ganoderma lucidum in Overweight Individuals: A Randomized Placebo-controlled trial. Med J Nutrition Metab. 2022;15(2):263-271. doi: 10.3233/MNM-211533
Aref M, Khoshhali M, Ghasemi P, Adeli S, Heidari‑Beni M, Kelishadi R. Effect of Ganoderma lucidum on serum lipid profiles: A systematic review and meta‑analysis on animal studies. J Res Med Sci. 2023;28(1):70. doi: 10.4103/ jrms.jrms_175_23
Klupp NL, Chang D, Hawke F, et al. Ganoderma lucidum mushroom for the treatment of cardiovascular risk fac-tors. Cochrane Database Syst Rev. 2015(2):CD007259. doi: 10.1002/14651858.CD007259.pub2
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
